Jazz Pharmaceuticals – $575 Million Exchangeable Senior Note Offering

San Francisco – September 22, 2017 – Cooley advised Jazz Pharmaceuticals plc on its completed Rule 144A offering of $575 million aggregate principal amount of 1.50% exchangeable senior notes due 2024 issued by its wholly-owned subsidiary, Jazz Investments I Limited. This offering also included the full exercise of the initial purchasers’ option to purchase up to an additional $75 million aggregate principal amount of notes. Chad Mills, Rob Phillips, Charlie Kim and Mischi a Marca led the Cooley team advising Jazz.

Jazz Pharmaceuticals (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.

Cooley recently advised Jazz Pharmaceuticals on its strategic agreement with ImmunoGen.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Chadwick Mills Partner, San Francisco
Robert Phillips Partner, San Francisco
Charlie Kim Partner, San Diego
Mischi a Marca Partner, San Francisco
Jason Savich Partner, San Francisco
Kristin VanderPas Partner, San Francisco
Sepideh Mousakhani Associate, Palo Alto
Denny Won Associate, San Francisco
Bill Boyle Paralegal Specialist, Palo Alto
Amanda Fant Associate, San Francisco
Susan Cooper Philpot Retired Partner, San Francisco
Mark Windfeld-Hansen Partner, Palo Alto
Francis Wheeler Partner, Colorado